Prof. PeptideProf. Peptide
Guide

How is ipamorelin dosed?

No trial has set an ipamorelin dose for the subcutaneous use clinics prescribe. Clinics commonly give it with CJC-1295 at 100 to 400 mcg of each by subcutaneous injection at bedtime, nightly or on 5 nights a week; on its own, the range reported is 100 to 300 mcg one to three times a day. Its three human studies all gave it intravenously, for a different purpose.

Topic: What clinics prescribe for ipamorelin, and why its trials describe a different route

Audience: Anyone comparing an ipamorelin dose figure against what was actually studied

Reading time: 8–10 minutes

Every trial used IV administration

The two registered Phase 2 trials studied intravenous ipamorelin for postoperative ileus — a hospital-inpatient indication treating GI paralysis after bowel surgery — and the one published pharmacokinetic study also used IV infusion, in healthy volunteers. None used subcutaneous injection, the route clinics prescribe. Every figure on this page is a fact about a specific study or a clinic’s published practice — not a recommendation.

What ipamorelin is, and what’s actually been tested

Ipamorelin is a synthetic pentapeptide developed by Novo Nordisk as a selective ghrelin receptor (GHSR-1a) agonist, intended to stimulate growth hormone release. It has not completed a Phase 3 trial. The ipamorelin profile covers the mechanism and broader research context; this page sets out the clinic doses and each trial’s own dosing.

Clinic practice comes first below, attributed to the clinics that publish it, then the published trial data, graded by design. All of the trial data here is intravenous, administered in a clinical or hospital setting — a materially different use than the subcutaneous injection clinics prescribe, and this page keeps that distinction visible throughout rather than presenting one dose figure as if it covered both.

How do clinics dose ipamorelin?

No trial has set a dose for the subcutaneous use clinics prescribe. Clinics commonly give ipamorelin together with CJC-1295, at 100 to 400 mcg of each by subcutaneous injection at bedtime, nightly or on 5 nights a week [8][9][10]. On its own, the range reported is 100 to 300 mcg one to three times a day, most often 200 to 300 mcg once at night on an empty stomach, starting near 100 to 200 mcg [6][8]. This is clinic practice, not a studied dose; the trials follow.

  • Titration: one clinic protocol for the pair gives 200 mcg of each nightly in month 1, then 400 mcg of each, 30 minutes before bed [9]; for ipamorelin alone, clinics start near 100 to 200 mcg once nightly and add a small increase or a second daily dose only after judging sleep and recovery [6].
  • Frequency: clinics commonly give it once nightly on 5 nights a week, describing the 5-days-on, 2-off pattern as a way to prevent desensitization [9][10]; the range reported runs up to one to three times a day [6][8].
  • Timing: at bedtime, often 1 hour before bed on an empty stomach [6][10]; clinics say alcohol within 2 hours of the dose blunts the growth-hormone response [9].
  • Side effects clinics list: injection-site reactions, headache, flushing, water retention or mild swelling, increased appetite and tiredness or light-headedness [7]; for the pair, one protocol guide puts water retention or facial puffiness at 15 to 25% of patients and tingling or numbness in the hands at 5 to 10% [9].
  • Who clinics exclude: active cancer, pregnancy and breastfeeding [7]; for the pair, also pituitary tumors and diabetic retinopathy [11].

Clinic practice diverges from every trial on this page in two ways at once: route (subcutaneous versus every trial’s intravenous administration) and how the dose is specified (a fixed microgram amount per injection, versus a body-weight-based dose — 0.03 or 0.06 mg/kg, that is 30 or 60 mcg/kg — in the trials). No published source derives the clinic figures from either the Gobburu pharmacokinetic data or the ileus trials’ dosing. The ipamorelin profile’s dosing section tabulates each clinic’s published protocol, and how often CJC-1295 and ipamorelin are dosed covers the pair’s schedule.

The ipamorelin reconstitution calculator and the peptide dosage calculator work out how much bacteriostatic water to add to a research-grade vial and how many syringe units a given amount takes. Neither sets a dose.

What the trials administered — all of them IV

Three studies exist. Each is graded against Prof. Peptide’s standing citation convention — a claim is attributed when it resolves to a named, checkable source. Two grade as attributed, published, peer-reviewed studies; the third is a registered, completed trial with no published or posted result, reported here as that absence rather than left out entirely.

Gobburu et al. 1999 — Pharmacokinetic/Pharmacodynamic Study

Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharm Res. 1999;16(9):1412–1416. PMID 10496658.

Design: Dose-escalation pharmacokinetic/pharmacodynamic study in healthy male volunteers. No efficacy or safety endpoint — the study characterizes disposition and GH response, not an indication.

Arms: 40 participants (8 healthy male subjects at each of 5 dose levels), IV infusion over 15 minutes at 4.21, 14.02, 42.13, 84.27, or 140.45 nmol/kg.

Endpoint reported: Dose-proportional pharmacokinetics: terminal half-life 2 hours, clearance 0.078 L/h/kg, volume of distribution at steady-state 0.22 L/kg. A single episode of GH release peaked at 0.67 hours post-infusion at every dose tested, with concentration for half-maximal GH stimulation (SC50) of 214 nmol/L.

Adverse events reported: No adverse-event data reported — safety was not a stated endpoint of this pharmacokinetic study.

Attributed — PubMed abstract, registered pharmacokinetic study. Characterizes disposition and GH response only; not evidence for any therapeutic dose.

Beck, Sweeney & McCarter 2014 — Postoperative Ileus (Phase 2 RCT)

NCT00672074

Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Int J Colorectal Dis. 2014;29(12):1527–1534. PMID 25331030.

Design: Multicenter, randomized, double-blind, placebo-controlled Phase 2 trial in hospital inpatients undergoing small or large bowel resection by open or laparoscopic surgery. Proof-of-concept design for postoperative ileus.

Arms: 117 patients enrolled (114 in the safety and modified intent-to-treat populations), randomized to IV ipamorelin 0.03 mg/kg (30 mcg/kg) or placebo, twice daily, from postoperative day 1 to 7 or hospital discharge.

Endpoint reported: Primary efficacy endpoint (time to tolerance of a standardized solid meal): 25.3 hours (ipamorelin) versus 32.6 hours (placebo), p=0.15 — not statistically significant. The paper's own conclusion states no significant differences between ipamorelin and placebo in the key or secondary efficacy analyses.

Adverse events reported: Any treatment-emergent adverse event: 87.5% (ipamorelin) versus 94.8% (placebo) — a lower rate on ipamorelin, per the paper's own reported figures.

Attributed — PubMed abstract, registered under an NCT number listed on ClinicalTrials.gov (Phase 2, COMPLETED, actual enrollment 117). This is a completed, peer-reviewed, randomized controlled trial — the strongest single piece of human evidence on this page — but a hospital IV study that missed its primary endpoint, not a subcutaneous dosing study.

Ipamorelin Compared to Placebo for GI Function Recovery (Phase 2, Unpublished)

NCT01280344

ClinicalTrials.gov registry record only — no peer-reviewed publication or posted results.

Design: Phase 2, randomized, double-blind, placebo-controlled dose-finding trial in patients following small or large bowel resection with primary anastomosis, for gastrointestinal dysmotility.

Arms: 320 participants (actual enrollment per the registry) randomized to IV ipamorelin 0.03 mg/kg (30 mcg/kg) twice daily, 0.06 mg/kg (60 mcg/kg) twice daily, 0.06 mg/kg three times daily, or matching placebo.

Endpoint reported: No results were ever posted to the ClinicalTrials.gov registry, and no peer-reviewed paper has been published. The registry marks the study COMPLETED with no results.

Adverse events reported: Not reported — no results exist to cite.

Topline absent — registered, completed, but with no published or posted outcome of any kind. Reported here as an absence: a 320-patient trial exists and ran to completion, but neither its efficacy nor its safety findings are available to attribute to anything.

Regulatory position: 503B Category 2, sport and a warning letter

Ipamorelin is not FDA-approved. FDA lists ipamorelin as nominated for 503A compounding and then withdrawn, so no FDA category currently covers 503A pharmacies compounding it from bulk; some clinics still list it [4][8][9][10].

On FDA’s bulk-substance safety-risk page, “Ipamorelin acetate” was also added to the active 503B Category 2 list on September 29, 2023, with the stated concern that “compounded drugs containing Ipamorelin acetate may pose risk for immunogenicity for certain routes of administration due to the potential for aggregation or peptide-related impurities.” The entry adds that a published study “identified serious adverse events including death when ipamorelin was administered intravenously for improving gastric motility,” and that FDA lacks safety information for other injectable routes. The same substance and the same language also appear in the 503A “bulk drug substances nominated but withdrawn” table — meaning it is not on the active 503A list either.

Clinics that prescribe ipamorelin state that it is not FDA-approved and is compounded by licensed 503A pharmacies [9], and note that FDA’s 2023 Category 2 listing restricted its compounding in the US [8]. In sport, the World Anti-Doping Agency’s 2026 Prohibited List names ipamorelin among growth hormone secretagogues under S2.2.4, prohibited at all times [12].

A specific FDA warning letter does name a compounded ipamorelin product: on January 26, 2022, FDA sent a warning letter (624782) to Innoveix Pharmaceuticals Inc., referencing a compounded “Semorelin/Ipamorelin 3 mg for subcutaneous or intramuscular injection” product the firm had voluntarily recalled. The letter’s stated concern is sterility assurance — deficient sterile drug-production practices at that specific firm — not a 503A or 503B eligibility finding about ipamorelin as a substance, and this page keeps that distinction intact rather than treating the two as the same kind of regulatory action.

Research-grade ipamorelin vials are sold for laboratory use only, not for human use; a research-use label does not make a vial an approved or prescribed product.

FAQ

How do clinics dose ipamorelin?
No trial has set a dose for the subcutaneous use clinics prescribe. Clinics commonly give it with CJC-1295 at 100 to 400 mcg of each by subcutaneous injection at bedtime, nightly or on 5 nights a week. On its own, the range reported is 100 to 300 mcg one to three times a day, most often 200 to 300 mcg once at night on an empty stomach, starting near 100 to 200 mcg. That differs from every trial on this page in route (subcutaneous versus intravenous) and in how the dose is set (a fixed microgram amount versus 0.03 or 0.06 mg/kg, that is 30 or 60 mcg/kg, in the trials). No published source derives the clinic figures from the trials.
Is there an FDA-approved ipamorelin product?
No. FDA lists ipamorelin as nominated for 503A compounding and then withdrawn, so no FDA category currently covers 503A pharmacies compounding it from bulk; some clinics still list it. No other regulator, including the EMA, has approved it, and it has never completed a Phase 3 trial.
What dose did the ipamorelin trials use?
All three studies used intravenous administration. Gobburu et al. 1999 used five ascending IV infusion doses from 4.21 to 140.45 nmol/kg over 15 minutes, in healthy volunteers, to characterize pharmacokinetics — not an indication or a recommended dose. Beck et al. 2014 (NCT00672074) used 0.03 mg/kg (30 mcg/kg) IV twice daily for up to 7 days, in hospital patients recovering from bowel surgery, to treat postoperative ileus. NCT01280344 tested 0.03 mg/kg (30 mcg/kg) IV twice daily, 0.06 mg/kg (60 mcg/kg) IV twice daily, and 0.06 mg/kg IV three times daily against placebo, for the same hospital indication, but never published results.
Were any of the trials done with subcutaneous injection?
No. All three used intravenous infusion — the two Phase 2 trials in a hospital-inpatient setting treating postoperative ileus, the pharmacokinetic study in a clinical research setting in healthy volunteers. None of them used the subcutaneous route clinics prescribe. This page states that distinction directly rather than presenting the IV trial doses as if they described subcutaneous use.
Did the postoperative ileus trial work?
No, not on its primary endpoint. Beck et al. 2014 reported median time to first tolerated meal was 25.3 hours with ipamorelin versus 32.6 hours with placebo — a numeric difference, but not statistically significant (p=0.15). The paper's own conclusion states there were no significant differences between ipamorelin and placebo in the key and secondary efficacy analyses.
What adverse events were reported in the trials?
In Beck et al. 2014, any treatment-emergent adverse event occurred in 87.5% of the ipamorelin group and 94.8% of the placebo group — a lower rate on ipamorelin, reported here precisely rather than described as comparable. The paper concludes the 0.03 mg/kg IV twice-daily dose was well tolerated over up to 7 days. Neither the Gobburu 1999 PK study nor NCT01280344 has published adverse-event data for Prof. Peptide to cite — NCT01280344 completed but never posted results.
What is ipamorelin's current FDA compounding status?
FDA lists ipamorelin as nominated for 503A compounding and then withdrawn, so no FDA category currently covers 503A pharmacies compounding it from bulk; some clinics still list it. Ipamorelin acetate is also on FDA's active 503B Category 2 list (added September 29, 2023), citing immunogenicity risk from potential aggregation or peptide-related impurities and a published report of serious adverse events, including death, with intravenous use for gastric motility. Clinics that prescribe it state it is not FDA-approved and is compounded by licensed 503A pharmacies. A separate FDA warning letter (Innoveix Pharmaceuticals, 2022) names a compounded Sermorelin/Ipamorelin product, but its stated concern was sterility assurance in that firm's sterile-compounding practices — not a 503A/503B eligibility finding about ipamorelin itself.

References

  1. Gobburu JV, Agersø H, Jusko WJ, Ynddal L. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res. 1999;16(9):1412–1416. PMID 10496658. https://pubmed.ncbi.nlm.nih.gov/10496658/
  2. Beck DE, Sweeney WB, McCarter MD; Ipamorelin 201 Study Group. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014;29(12):1527–1534. PMID 25331030. ClinicalTrials.gov NCT00672074. https://clinicaltrials.gov/study/NCT00672074
  3. ClinicalTrials.gov. Safety and Efficacy of Ipamorelin Compared to Placebo for the Recovery of Gastrointestinal Function, NCT01280344. https://clinicaltrials.gov/study/NCT01280344
  4. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  5. U.S. Food and Drug Administration. Warning Letter: Innoveix Pharmaceuticals Inc., reference 624782, 2022-01-26. https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/innoveix-pharmaceuticals-inc-624782-01262022
  6. Clinic: Pru, Ipamorelin dosage (updated July 9, 2026). Cited for its dose range, the common nightly dose, titration and timing. Read November 6, 2026. https://joinpru.com/blog/ipamorelin-dosage
  7. Clinic: Pru, Ipamorelin guide. Cited for its side-effect list and who it is not for. Read November 6, 2026. https://joinpru.com/blog/ipamorelin-guide
  8. Clinic: Chia Health, Ipamorelin growth hormone peptide guide (updated August 24, 2026). Cited for clinic doses alone (100–300 mcg, 1–3 times a day) and with CJC-1295 (100 mcg each), and the 2023 Category 2 listing. Read November 6, 2026. https://chia.health/blog/ipamorelin-growth-hormone-peptide-guide
  9. Clinic: Rx Peps Direct, CJC-1295 / Ipamorelin protocol guide (medically reviewed by Jonathan Snipes, MD). Cited for its titration, timing, alcohol caution, side-effect frequencies and 503A status. Read November 6, 2026. https://www.rxpepsdirect.com/guides/cjc-ipamorelin
  10. Clinic: Relive Health Houston Memorial, CJC-1295 / Ipamorelin. Cited for its timing (1 hour before bedtime, empty stomach) and five-days-on, two-off schedule. Read November 6, 2026. https://relivehealth.com/memorial-houston-tx/peptide-therapy/cjc-1295-ipamorelin/
  11. Clinic: Rx Peps Direct, CJC-1295 / Ipamorelin product page. Cited for who it is not suitable for. Read November 6, 2026. https://www.rxpepsdirect.com/peptides/muscle-growth/cjc-ipamorelin
  12. World Anti-Doping Agency. The Prohibited List 2026, S2.2.4 (valid January 1, 2026; read October 26, 2026, as on the ipamorelin profile). https://www.wada-ama.org/en/prohibited-list

Affiliate disclosure: Prof. Peptide earns a commission on purchases and sign-ups made through its links and codes, at no extra cost to the buyer. Commissions never decide which vendors are listed, how they are ranked or verified, or what Prof. Peptide concludes.

Checked and updated